BioGenCell is pioneering advancements in cellular medicine through its innovative TRACT (Tissue Regenerative Activated Cell Therapy) technology, which focuses on personalized cell therapy for patients suffering from degenerative microvascular diseases. This approach utilizes the patient's own cells, processed to mimic natural bodily functions, to create tailored treatments that are both safe and effective. The therapy is designed to be accessible and user-friendly for both patients and healthcare providers, aiming to halt disease progression, alleviate pain, and enhance overall functionality. The treatment process involves a simple three-step procedure: blood collection, processing, and administration, allowing for rapid production and application of the therapy within a single appointment.

The company is currently conducting a Phase 2 clinical trial for its lead product, BGC101, which targets Chronic Limb-Threatening Ischemia (CLTI). This trial aims to evaluate the safety and efficacy of the cell therapy in providing amputation-free survival for patients who have exhausted other treatment options. BioGenCell's technology not only addresses the urgent need for effective therapies in vascular diseases, which account for a significant percentage of global mortality, but also seeks to reduce the financial burden associated with traditional treatment methods. By harnessing the power of the immune system and stem cells, BioGenCell is committed to transforming the landscape of treatment for various degenerative conditions, with a focus on improving patient outcomes and quality of life.

Israel

BioGenCell was founded with the vision of developing safe, effective, and long-lasting effective treatment for incurable, blood vessel diseases that will be both accessible and patient friendly.

Our disruptive TRACT technology platform provides a comprehensive approach for rapid manufacturing and commercialization of cell-therapies.

BioGenCell

Company Details